April 2021 in “HIV & AIDS Review” Glycyrrhizinic acid spray showed limited effectiveness in treating anogenital warts in HIV patients with low CD4 levels.
40 citations
,
December 2019 in “Neurobiology of Stress” Neuroactive steroids show promise for treating mental and neurological disorders by targeting GABA_A receptors.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
May 2025 in “Clinical Proteomics” Key proteins and potential drugs for treating alopecia areata were identified.
July 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
1 citations
,
August 2021 in “Consilium Medicum” Selencin effectively reduces hair loss and improves hair health in diffuse alopecia.
November 2025 in “Frontiers in Pharmacology” Gentamicin-loaded exosomes improve healing of infected diabetic wounds in mice.
1 citations
,
March 2023 in “Science Translational Medicine” Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
July 2022 in “Journal of Investigative Dermatology” Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.
January 2016 in “Global dermatology” A treatment called Cellcurin, combined with microneedling, significantly increased hair density and diameter in patients with hair loss.
22 citations
,
September 2024 in “Chemical Engineering Journal” A new microneedle patch effectively and safely treats alopecia areata.
December 2023 in “International journal of multidisciplinary research and analysis” SH-MSCs gel can effectively treat alopecia by increasing IL-10 and decreasing TNF-α gene expression.
November 2015 in “Journal of the Korea Academia-Industrial cooperation Society” The new assay can help develop products for hair re-growth.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
57 citations
,
September 2017 in “Journal of controlled release” Nanocarrier-loaded gels improve drug delivery for cancer, skin conditions, and hair loss.
3 citations
,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
October 2025 in “Asian Journal of Oral Health and Allied Sciences” Autologous growth factor concentrate therapy shows promise for treating early-stage hair loss safely and effectively.
13 citations
,
April 2019 in “American Journal of PharmTech Research” Emulgels effectively deliver hydrophobic drugs for skin conditions like acne and psoriasis.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” Golvatinib shows promise as a treatment for Omicron in elderly patients.
September 2024 in “Egyptian Journal of Dermatology and Venerology” Combining TRA and latanoprost is most effective for treating localized alopecia areata.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
April 2026 in “Clinical and Experimental Dermatology” The Dupilumab Italian Prurigo Nodularis (DUPItaPN) study evaluated the long-term effectiveness and safety of dupilumab in 543 adults with prurigo nodularis (PN) over 104 weeks. The study found that dupilumab significantly improved symptoms, with the mean Worst Itch Numeric Rating Scale (WI-NRS) score decreasing from 8.7 to 1.7, and 86.8% of patients achieving a ≥4-point reduction by week 104. Additionally, 81.2% of patients reached an Investigator Global Assessment for PN-Stage (IGA PN-S) of 0/1. The Dermatology Life Quality Index (DLQI) improved from 17.4 to 2.6. Dupilumab was well tolerated, with only 2.9% discontinuing due to adverse events, and no cancer progression or viral reactivation observed. The study supports dupilumab as a long-term treatment option for moderate-to-severe PN, even in elderly and comorbid patients.
10 citations
,
April 1964 in “Journal of the American Geriatrics Society” Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.